Career Management & Planning
Business Report
Submitted to:
Madam Hafsa
Submitted by:
Waheed Shahmir (3422)
Sajad Ali
Ayaz Ali
Zeeshan Dhamra
Abdul Basit Boto
Atif Saudozai
Ali Khan
Course:
BBA Sixth
(3423)
Acknowledgement
First of all I am thankful to Almighty Allah, Who gave me the ability to
understand the mechanics of this subject and enabled me to complete this assignment
successfully.
We are very grateful to Col Zafar Baloch (Director Sales & Exports) at Wnsfield
Pharmaceutical, without whose co-operation and support this business report would
not have been possible.
WnsField Pharmaceuticals
Company Background
WnsFeild Pharmaceuticals, an ISO 9001 and 14001 Generic Drug
Manufacturing Company which is an affiliatory unit of W-Group of Industries. W-Group
of Industries was founded in 2005 which at the moment has seven Units. WnsFeild
believes in progress through hard work and ethical practices. They are also very much
mindful about our Corporate Social Responsibilities (CSR) beyond their conventional
business role. They understand that people have very emotional association with their
Group image; who expect them to play significant part in their lives. While being
sensitized with the expectation of the customers they have always tried to play a
frontline role towards helping the humanity.
At Wnsfeild Pharmaceuticals, they provide ample chances for professional
services as well as numerous employment opportunities in multiple fields. They
actually invest into their staff through providing them equitable chances of personal
and professional growth, trainings and social security. This is the way they gain their
unflinching commitment to their corporate goals and other social responsibilities.
The unit operates state of the art manufacturing facility, fully compliant with
CGMP. The production unit is located in Industrial Estate Hattar, 51 kms North of
Islamabad, and is in production for the last about six years. It commits itself for its
unflinching faith in conformance of CGMP (current good manufacturing practices) and
strict adherence to quality control procedures.
WnsFeild Pharmaceuticals is equipped with latest machinery, skillful, talented and
motivated management and workers, who can deliver both quality and quantity. They
are supplying good quality and affordable medicines to local market as well as
government institutions. They are also exporting to Afghanistan through well reputed
distributers. They are also in process of registration of their products in Philippines,
Myanmar and Vietnam. Their international outlook has brought them more strength
and confidence.
They are always in search of ways and means to improve their performance
towards fulfilling their commitments and manufacturing good quality medicines.
Mission Statement
We strive to produce quality medicines, that conform to CGMP requirements and
cater the health care needs of not only the local but international markets as well.
Vision Statement
To become a leading pharmaceutical company of Pakistan which serves the nations
ailing community with quality and affordable medicines, and to extend its efforts to
help provide good health to international community.
Core Values
We must not make shortcuts and must not stray from ethical path.
We recognize that ability to excel depends on the following:
Integrity
Knowledge
Skill
Teamwork
Creativity
Motivation
Objectives
To employ cutting edge technologies that are environment friendly and always strive
to achieve zero defect products by meeting international standards. To work
tirelessly to provide the highest quality and affordable medicines to the ailing
community, thereby contributing to the betterment of society.
Strategy
Wnsfield pharmaceutical are using a hybrid of low cost and differentiation strategy
with an aim of providing desired Quality, Value, Features, Performance and Service
Attributes while beating rivals on price.
Corporate Governance
1.
The firm has three executive directors and they own significant
amount of shares of the firm.
MD and CEO Mr Arshad Mahmood
Director Marketing and Sales Lt Col (R) Zafar
Mahmood Khan
Director Operations Mr Shehzad
2.
MD contributes to the firm in terms of knowledge, skills, background,
and connections. The firm has started international operations and
Director marketing and sales has attended international exhibitions.
3.
These directors are also present on board and have been contributing
to it immensely for past nine years.
SWOT ANALYSIS
Variety of registered drugs
present in firms product
portfolio
Stringent Quality Controls
Turnover of employees
Non registration of desired
medicines
Government Policies
Exchange rate fluctuation
Inflation risk
Terrorism
Political instability
measures in place
Efficient capacity management
Customer Care is foremost on
Financial Impications
A weak Online Presence
Lack of highly skilled and
technical Labor
Top Management mind
Focus on single activity i.e.
Manufacturing(to lower costs)
Looser Regulations will allow
Wnsfield perform in a way that
is advantageous for them and
their customers
Upgradation of technological
equipment
Market Growth opportunities
Related Products
Induction of new products to
diversify portfolio and expand
business
Online Market offers ability to
reach wider audience
PEST ANALYSIS
POLITICAL CHANGE
Political factors include government regulations and legal issues and define both
formal and informal rules under which the firm must operate. Some examples
include:
Tax policy
Employment laws
Environmental regulations
Trade restrictions and tariffs
Political stability
NATURE OF CHANGE
In pharmaceutical industry prices are fixed by ministry of health. It exposes a
significant risk on pharmaceutical industry.
IMPACT OF CHANGE
Profit margin of pharmaceutical industry will be reduced due to price fixation policy.
ECONOMIC CHANGE
Economic factors affect the purchasing power of potential customers and the firm's
cost of capital. The following are examples of factors in the macro economy:
Economic growth
Interest rates
Exchange rates
Inflation rate
NATURE OF CHANGE
Inflation and exchange rate fluctuations are important factors influencing
pharmaceutical industry of Pakistan because raw material such as molecules and
supporting material is imported.
IMPACT OF CHANGE
Inflation and exchange rate fluctuations expose a risk of increase in cost
because main cost involved in pharmaceuticals is import of raw material.
SOCIAL CHANGE
Social factors include the demographic and cultural aspects of the external
macro environment. These factors affect customer needs and the size of potential
markets. Some social factors include:
Health consciousness
Population growth rate
Age distribution
Career attitudes
Emphasis on safety
NATURE OF CHANGE
Population is increasing day by day resulting in increased demand of pharmaceutical
products. Cross border relationships have also strong influence on pharmaceutical
industry of Pakistan. Supporting material is imported from India and China. So, cross
border situations of India and Pakistan do matter. Terrorism and global alliance are
also important factors stimulating the standing of pharmaceutical industry of
Pakistan.
IMPACT OF CHANGE
Diseases are increasing day by day due to increase in population. Sales will be
reduced due to cross border relationship and terrorism activities. Due to global
alliance market share increases.
TECHNOLOGICAL CHANGE
Technological factors can lower barriers to entry, reduce minimum efficient
production levels, and influence outsourcing decisions. Some technological factors
include:
R&D activity
Automation
Technology incentives
Rate of technological change
NATURE OF CHANGE
Technology is changing day by day. Pharmaceutical industry should acquire new
and advanced technologies to compete in the market.
IMPACT OF CHANGE
Massive production is possible through advanced technologies by which they can
achieve economies of scale.
LEGAL CHANGE
Drug Regulatory Authority of Pakistan (DRAP) has significantly slow process
for registration of medicines by the firms. It hinders the business speed as no
production can be made without the registration of drugs by any firm.
Punjab Government has recently amended the drug act against spurious
medicines. The amendment has not been welcomed by the pharmaceutical
industry as it poses serious threat to the manufacturers.
Tab Sofosbuvir is a nucleotide analog used in combination with other drugs
for the treatment of hepatitis C virus infection. It has been marketed
internationally since 2013. The same has been requested by the firm for
registration but response of DRAP is unsatisfactory.
ENVIRONMENTAL CHANGE
Climate, including global temperature, sea level, and fresh water availability
Weather, and Solar phenomena in Pakistan dont generally affect much the firm and
the pharmaceutical industry. However, these forces may have different effects in
other regions of the world.
FIVE FORCES ANALYSIS
COMPETITIVE INTENSITY
So far as industry analysis is concerned it implies that rivalry among existing firms in
pharmaceutical industry is almost at moderate level. Pharmaceutical companies are
competing on the basis of quality, cost, product range and research and
development.
BARGAINING POWER OF SUPPLIERS
Pharma industry depends upon several organic chemicals. Very competitive and
fragmented industry where chemicals are largely a commodity. Suppliers have very
low bargaining power. Pharma industry can switch from their suppliers without
incurring a very high cost.
BARGAINING POWER OF CUSTOMERS
End user of the product is different from the influencer (Doctors).Consumer has no
choice but to buy what doctor says. Buyers are scattered and they as such does not
wield much power in the pricing of the products.
THREAT OF NEW ENTRANT
Pharmaceutical industry of Pakistan is growing rapidly and there is still significant
potential for growth. There are chances of some new entrants but this threat is at
moderate level. It is not easy to establish a new pharmaceutical company in Pakistan
due to requirement of huge investment.
THREAT OF SUBSTITUTES
Research and development are the essence of pharmaceutical industry. Every
pharmaceutical company in Pakistan is making efforts for the betterment of their
research and development department. Still there is a significant threat of substitute
products because of rising discoveries and pacing research and development in the
whole world.
FIRM VALUE CHAIN
Primary Activities:
Operations
a.
The firms operations are need and budget driven, however they
are
generally consistent with firms mission, objectives, strategies, and policies and with
internal and external environments.
b.
Purchasing is being handled appropriately. The suppliers and distributors are
operating in an environmentally sustainable manner. The firm have 10 operating
sections for production of Tablets and injections etc.
c.
The operations managers are using appropriate concepts and techniques to
evaluate and improve current performance. The cost systems, quality control and
reliability systems, inventory control management, personnel scheduling, TQM,
learning curves, safety programs, and engineering programs are positively effecting
the efficiency of manufacturing.
Administration
a.
Current Information System is capable of providing sufficient feedback on
implementation activities and performance.
1.
The performance results can be pinpointed by area, unit, project, or function.
2.
The information sharing is timely.
3.
Leading firms are being followed to evaluate the functions and activities
b.
Adequate Control Measures are in place to ensure conformance with the
recommended strategic plan.
1.
Appropriate standards and measures are being used.
2.
Reward systems is capable of recognizing and rewarding good performance.
3.
Sales incentives are being offered for promotion of sales and market share.
Secondary Activities:
Marketing
a.
Following are the firms current marketing objectives, strategies, policies, and
programs:i.
They have franchising at national and provincial levels. A continuous effort is
being made to promote the structure at district levels.
ii.
The objectives are budget driven and contained due to non-availability of
specialized manpower.
b.
Only registered drugs can be produced by the firm, which is being done
sufficiently. Firm is gaining market share progressively.
Research and Development (R&D)
a.
The firm is carrying out limited research and development in the required field,
remaining within the parameters of requirement and budget availability. The
technology is being used for analyzing the market trends of different drugs.
b.
The firm is competent in technology transfer. It uses concurrent engineering
and cross-functional work teams in product and process design.
c.
The firms investment in R&D can be compared with the investments of similar
firms.
Human Resources Management (HRM)
a.
The firm always make efforts to get the qualified, trained and professional
intake in all the sectors. HRM is being given due importance at top level.
Recruitment and selection is done on merit. Woman are given equal service
opportunity at all levels.
b.
The firm is encouraging the HR policies and are being implemented n true
later and spirits.
c.
The firms HRM performance can be compared with that of other similar firms.
d.
HRM managers are using appropriate concepts and techniques to evaluate
and improve firm performance. job analysis program, performance appraisal
system, up-to-date job descriptions, training and development programs, attitude
surveys, job design programs, quality of relationships with unions, and use of
autonomous work teams.
e.
The firm is managing the diversity of its workforce to the benefit of the firm.
Information Technology (IT)
a.
The firm is using IT adequately for routine work. Use of different software is
encouraged. The firm is investing sufficient on IT structure to be placed in position.
b.
The firm is involved in IT performing in terms of providing a useful database,
automating routine clerical operations, assisting managers in making routine
decisions, and providing information necessary for strategic decisions.
